Anthony Federico

Anthony Federico

Auto-generated profile, based on publicly available information

Anthony Federico

Boston University, Boston, MA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 March 2020 in Nature
Verified
Journal Article
Closed access
PDF file
QDQiaohong Duan
Qiaohong Duan
MLMing-Che James Liu
Ming-Che James Liu
DKDaniel Kita
Daniel Kita
SJSamuel S. Jordan
Samuel S. Jordan
FYFang-Ling Jessica Yeh
Fang-Ling Jessica Yeh
ACAlice Y. Cheung
Alice Y. Cheung

28 November 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
JKJoseph G. Kern
Joseph G. Kern
ATAndrew Tilston-Lunel
Andrew Tilston-Lunel
AFAnthony Federico
Anthony Federico
BNBoting Ning
Boting Ning
AMAmy Mueller
Amy Mueller
XVXaralabos Varelas
Xaralabos Varelas
Basal-like breast cancers, an aggressive breast cancer subtype that has poor treatment options, are thought to arise from luminal mammary epithelial cells that undergo basal plasticity through poorly understood mechanisms. Using genetic mouse models and ex vivo primary organoid cultures, we show that conditional co-deletion of the LATS1 and LATS2 kinases, key effectors of Hippo pathway signaling, in mature mammary luminal epithelial cells promotes the development of Krt14 and Sox9-expressing basal-like carcinomas that metastasize over time. Genetic co-deletion experiments revealed that phenotypes resulting from the loss of LATS1/2 activity are dependent on the transcriptional regulators YAP/TAZ. Gene expression analyses of LATS1/2-deleted mammary epithelial cells notably revealed a transcriptional program that associates with human basal-like breast cancers. Our study demonstrates in vivo roles for the LATS1/2 kinases in mammary epithelial homeostasis and luminal-basal fate control and implicates signaling networks induced upon the loss of LATS1/2 activity in the development of basal-like breast cancer.

1 January 2021 in Patterns
Verified
Journal Article
Open access
AFAnthony Federico
Anthony Federico
SMStefano Monti
Stefano Monti
Protein-protein interaction (PPI) databases are an important bioinformatics resource, yet existing literature-curated databases usually represent cell-type-agnostic interactions, which is at variance with our understanding that protein dynamics are context specific and highly dependent on their environment. Here, we provide a resource derived through data mining to infer disease- and tissue-relevant interactions by annotating existing PPI databases with cell-contextual information extracted from reporting studies. This resource is applicable to the reconstruction and analysis of disease-centric molecular interaction networks. We have made the data and method publicly available and plan to release scheduled updates in the future. We expect these resources to be of interest to a wide audience of researchers in the life sciences.

18 May 2023 in PLOS Computational Biology
Verified
Journal Article
Open access
PDF file
AFAnthony Federico
Anthony Federico
JKJoseph Kern
Joseph Kern
XVXaralabos Varelas
Xaralabos Varelas
SMStefano Monti
Stefano Monti
Inference of biological network structures is often performed on high-dimensional data, yet is hindered by the limited sample size of high throughput “omics” data typically available. To overcome this challenge, often referred to as the “small n, large p problem,” we exploit known organizing principles of biological networks that are sparse, modular, and likely share a large portion of their underlying architecture. We present SHINE—Structure Learning for Hierarchical Networks—a framework for defining data-driven structural constraints and incorporating a shared learning paradigm for efficiently learning multiple Markov networks from high-dimensional data at large p/n ratios not previously feasible. We evaluated SHINE on Pan-Cancer data comprising 23 tumor types, and found that learned tumor-specific networks exhibit expected graph properties of real biological networks, recapture previously validated interactions, and recapitulate findings in literature. Application of SHINE to the analysis of subtype-specific breast cancer networks identified key genes and biological processes for tumor maintenance and survival as well as potential therapeutic targets for modulating known breast cancer disease genes.

15 September 2023 in Clinical Cancer Research
Verified
Journal Article
Open access
AFAnthony Federico
Anthony Federico
EREric Reed
Eric Reed
MKMaria Kukuruzinska
Maria Kukuruzinska
XVXaralabos Varelas
Xaralabos Varelas
SMStefano Monti
Stefano Monti
The ever-increasing availability of publicly available cancer omics datasets makes it possible to perform in-silico studies aimed at elucidating disease mechanisms of action (MOAs) that may aid in therapeutic development. To this end, we recently developed Structure Learning for Hierarchical Networks (SHiNe) to model and distinguish direct and indirect signaling interactions from gene expression data to identify key signaling “hubs” and “bottlenecks”, associated crosstalk, and downstream targets that we used to identify potential effectors of head and neck squamous carcinoma (HNSC). SHiNe is an advanced gene regulatory network reconstruction approach optimized for learning multiple Markov networks in the “large p, small n” settings (i.e., large number of genes, small number of samples) typical of omics data. We applied SHiNe to the analysis of TCGA-HNSC RNA-seq data to learn HPV-negative and subtype- specific networks for previously validated molecular subtypes (Atypical, Basal, Classical, and Mesenchymal). SHiNe learned networks were sparser, with higher clustering coefficients, and more significantly enriched for protein-protein interactions than randomly simulated networks. Further annotation of the learned networks with multiple layers of omics information revealed several highly eigen-central genes in the HPV-negative network to be characterized by additional omics features. Examples included EP300, ranked 2nd by eigen-centrality with a single somatic mutation (SSM) rate of 7.87% (versus 4.59% in all other TCGA tumors), MYH9 (rank=12, SSM=6.1%), RPS6KA4 (rank=39, CNV Gain=16.5%), GNAI3 (rank=45, CNV Loss=10.55%), and CFL1 (rank=51, CNV Gain=20.72%). Community detection in the HPV(-) network structure using the Walktrap algorithm yielded 33 signaling communities, with the highest centrality community encompassing most of the central genes within the network (e.g., KLHL11, EP300, TAOK1, ADAM17, APAF1) and including genes strongly enriched for DNA repair and maintenance pathways. Co-localization analysis of omics features in the HPV-negative network identified within the most central community revealed a cluster of genes with copy number variation gain ≥ 25%, including ABCC5, ACTL6A, AP2M1, ATP11B, MAP3K13, NCBP2, PAK2, PIK3CA, PLD1, PRKCI, SKIL, TBL1XR1, and ZMAT3, with most of these genes located on the q arm of chromosome 3. While amplification of 3q26-29 is a known characteristic of HNSCC associated with poorer patient outcome, the MOA remains unclear, and thus our network analysis offers an opportunity to identify meaningful signaling interactions for therapeutic intervention of 3q26-29 mutated tumors. Indeed, we have identified candidate associations with the 3q26-29 amplicon genes that we are currently validating. We are also developing a graphical interface for the interactive inspection of the inferred networks. Taken together, these results highlight the potential for network-based analysis to support the study and identification of novel candidate regulators of head and neck tumorigenesis. Citation Format: Anthony Federico, Eric Reed, Maria Kukuruzinska, Xaralabos Varelas, Stefano Monti. Gene regulatory network connectivity analysis identifies novel candidate effectors of HNSC tumorigenesis [abstract]. In: Proceedings of the AACR-AHNS Head and Neck Cancer Conference: Innovating through Basic, Clinical, and Translational Research; 2023 Jul 7-8; Montreal, QC, Canada. Philadelphia (PA): AACR; Clin Cancer Res 2023;29(18_Suppl):Abstract nr PO-020.